166 related articles for article (PubMed ID: 38250737)
21. Prediction of complete regression in fertility-sparing patients with endometrial cancer and apical hyperplasia: the GLOBAL model in a large Chinese cohort.
Li X; Wang Y; Wang J; Fan Y; Wang J
J Transl Med; 2024 Feb; 22(1):127. PubMed ID: 38308352
[TBL] [Abstract][Full Text] [Related]
22. Conservative re-treatment of women with atypical endometrial hyperplasia and early endometrial carcinoma: We can hope, at least.
Raffone A; Raimondo D; Rovero G; Travaglino A; Lopez G; Di Maio CM; Neola D; Raspollini A; Renzulli F; Filippelli A; Casadio P; Seracchioli R; Guida M
Int J Gynaecol Obstet; 2024 May; 165(2):542-551. PubMed ID: 37772342
[TBL] [Abstract][Full Text] [Related]
23. Management options and fertility-preserving therapy for premenopausal endometrial hyperplasia and early-stage endometrial cancer.
Gressel GM; Parkash V; Pal L
Int J Gynaecol Obstet; 2015 Dec; 131(3):234-9. PubMed ID: 26384790
[TBL] [Abstract][Full Text] [Related]
24. Prolonged conservative treatment in patients with recurrent endometrial cancer after primary fertility-sparing therapy: 15-year experience.
Wang Y; Yu M; Yang JX; Cao DY; Yuan Z; Zhou HM; Zhang Y; Li L; Shen K; Wu H
Int J Clin Oncol; 2019 Jun; 24(6):712-720. PubMed ID: 30746595
[TBL] [Abstract][Full Text] [Related]
25. Oncologic and obstetrical outcomes after fertility-preserving retreatment in patients with recurrent atypical endometrial hyperplasia and endometrial cancer.
He Y; Wang Y; Zhou R; Wang J
Int J Gynecol Cancer; 2020 Dec; 30(12):1902-1907. PubMed ID: 33051245
[TBL] [Abstract][Full Text] [Related]
26. Oncological and reproductive outcomes of endometrial atypical hyperplasia and endometrial cancer patients undergoing conservative therapy with hysteroscopic resection: A systematic review and meta-analysis.
Zhao S; Zhang J; Yan Y; Tian L; Chen L; Zheng X; Sun Y; Tian W; Xue F; Wang Y
Acta Obstet Gynecol Scand; 2024 Feb; ():. PubMed ID: 38382917
[TBL] [Abstract][Full Text] [Related]
27. The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer.
Guan J; Chen XJ
Front Endocrinol (Lausanne); 2022; 13():1041535. PubMed ID: 36387903
[TBL] [Abstract][Full Text] [Related]
28. Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study.
Giampaolino P; Di Spiezio Sardo A; Mollo A; Raffone A; Travaglino A; Boccellino A; Zizolfi B; Insabato L; Zullo F; De Placido G; Bifulco G
J Minim Invasive Gynecol; 2019; 26(4):648-656. PubMed ID: 30017893
[TBL] [Abstract][Full Text] [Related]
29. Significance of serum and pathological biomarkers in fertility-sparing treatment for endometrial cancer or atypical hyperplasia: a retrospective cohort study.
Wang Y; Zhou R; Zhang X; Liu H; Shen D; Wang J
BMC Womens Health; 2021 Jun; 21(1):252. PubMed ID: 34162378
[TBL] [Abstract][Full Text] [Related]
30. The pregnancy and oncology outcome of fertility-sparing management for synchronous primary neoplasm of endometrium and ovary.
Gama Q; Luo S; Wu P; Wang L; Liu S; Zhang H; Sun L; Wang Y; Yu M; Chen X; Shan W; Luo X
J Ovarian Res; 2023 Dec; 16(1):235. PubMed ID: 38062462
[TBL] [Abstract][Full Text] [Related]
31. Dusp6 immunohistochemistry is associated with the response of atypical endometrial hyperplasia and early endometrial cancer to conservative treatment.
Travaglino A; Raffone A; Gencarelli A; Micheli M; Franco L; Zullo F; Mollo A; Di Spiezio Sardo A; Bifulco G; Insabato L
Int J Gynaecol Obstet; 2022 Sep; 158(3):742-747. PubMed ID: 34837386
[TBL] [Abstract][Full Text] [Related]
32. Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia: A meta-analysis and systematic review.
Wei J; Zhang W; Feng L; Gao W
Medicine (Baltimore); 2017 Sep; 96(37):e8034. PubMed ID: 28906392
[TBL] [Abstract][Full Text] [Related]
33. Fertility preserving management of early endometrial cancer in a patient cohort at the department of women's health at the university of Tuebingen.
Andress J; Pasternak J; Walter C; Kommoss S; Krämer B; Hartkopf A; Brucker SY; Schönfisch B; Steinmacher S
Arch Gynecol Obstet; 2021 Jul; 304(1):215-221. PubMed ID: 33606091
[TBL] [Abstract][Full Text] [Related]
34. Association of ABO blood groups with ovarian reserve: a retrospective cohort study in Chinese Han women younger than 40 years with infertility.
Sun X; Sun C; Meng M; Liu L
J Ovarian Res; 2022 Dec; 15(1):132. PubMed ID: 36539903
[TBL] [Abstract][Full Text] [Related]
35. Use of clinicopathological factors to predict prognosis of fertility-sparing treatment for endometrial endometrioid carcinoma and atypical hyperplasia.
Zhang X; Zhao X; Wang C; Lu S; Wang Y; He Y; Wang J; Shen D
Oncol Lett; 2023 Feb; 25(2):52. PubMed ID: 36644134
[TBL] [Abstract][Full Text] [Related]
36. IVF impact on the risk of recurrence of endometrial adenocarcinoma after fertility-sparing management.
Vaugon M; Peigné M; Phelippeau J; Gonthier C; Koskas M
Reprod Biomed Online; 2021 Sep; 43(3):495-502. PubMed ID: 34315696
[TBL] [Abstract][Full Text] [Related]
37. Hysteroscopic treatments for endometrial malignancies and premalignancies: state of the art.
Kahramanoglu I
Minim Invasive Ther Allied Technol; 2021 Oct; 30(5):272-277. PubMed ID: 34289318
[TBL] [Abstract][Full Text] [Related]
38. Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia.
Fan Y; Li X; Wang J; Wang Y; Tian L; Wang J
Reprod Biol Endocrinol; 2021 Aug; 19(1):118. PubMed ID: 34344384
[TBL] [Abstract][Full Text] [Related]
39. Analysis of immunohistochemical characteristics and recurrence after complete remission with fertility preservation treatment in patients with endometrial carcinoma and endometrial atypical hyperplasia.
Li L; Xiao Z; Wang Y; He Y; Wang Z; Shen D; Wang J
Arch Gynecol Obstet; 2023 Jun; 307(6):2025-2031. PubMed ID: 35098335
[TBL] [Abstract][Full Text] [Related]
40. Membrane expression of the death ligand trail receptors DR4 and DR5 in the normal endometrium, endometrial atypical hyperplasia and endometrioid endometrial cancer.
Gottwald L; Szwalski J; Piekarski J; Pasz-Walczak G; Kubiak R; Spych M; Suzin J; Tyliński W; Sęk P; Jeziorski A
J Obstet Gynaecol; 2013 Jul; 33(5):512-8. PubMed ID: 23815209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
